Ameriprise
CLBT icon

Ameriprise’s Cellebrite CLBT Stock Holding History

Ameriprise’s Portfolio CLBT Stock Details CLBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-11,831
Closed -$219K – 4098
2025
Q3 		$219K Buy
11,831
+159
+1% +$2.5K ﹤0.01% 3885
2025
Q2 		$187K Sell
11,672
-73,310
-86% -$1.31M ﹤0.01% 3823
2025
Q1 		$1.65M Buy
+84,982
New +$1.79M ﹤0.01% 2996

Other funds holding CLBT

TWCM
True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
PP
Pertento Partners London, United Kingdom $1.37B AUM 36.36% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

Ameriprise's CLBT Position: Q4 2025 in Review

Ameriprise sold out of Cellebrite (CLBT) in Q4 2025, closing a stake of 11,831 shares — an estimated $219K sold.

Ameriprise first reported a position in CLBT in Q1 2025 and held it in 3 quarters. The position peaked at $1.65M in Q1 2025. 208 funds tracked by Wall St. Rank hold CLBT as of Q4 2025.

  • Ameriprise reported no remaining Cellebrite position as of Q4 2025 after selling out during the quarter.
  • Ameriprise sold 11,831 Cellebrite shares in Q4 2025, an estimated $219K.
  • Ameriprise first reported a position in Cellebrite in Q1 2025 and held it in 3 quarters.
  • Ameriprise's Cellebrite position peaked at $1.65M in Q1 2025.
  • 208 funds tracked by Wall St. Rank held Cellebrite as of Q4 2025.

Based on Ameriprise's 13F filing for Q4 2025, filed 17 Feb 2026.